220 related articles for article (PubMed ID: 12642972)
1. Adverse drug reactions, MedWatch reporting and medical student education.
Lewis LD; Nierenberg DW
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):93-5. PubMed ID: 12642972
[No Abstract] [Full Text] [Related]
2. Improving the quality of adverse drug reaction reporting by 4th-year medical students.
Rosebraugh CJ; Tsong Y; Zhou F; Chen M; Mackey AC; Flowers C; Toyer D; Flockhart DA; Honig PK
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):97-101. PubMed ID: 12642973
[TBL] [Abstract][Full Text] [Related]
3. Toward improved adverse event/suspected adverse drug reaction reporting.
Gross R; Strom BL
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
[No Abstract] [Full Text] [Related]
4. The MedWatch Program.
Love L; Couig MP
J Toxicol Clin Toxicol; 1999; 37(6):803-7. PubMed ID: 10584596
[No Abstract] [Full Text] [Related]
5. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
6. Submitting reports of adverse drug reactions to AJHP.
Thompson CA
Am J Hosp Pharm; 1994 Oct; 51(19):2358. PubMed ID: 7847399
[No Abstract] [Full Text] [Related]
7. Monitoring for adverse drug events.
Kennedy DL; Goldman SA
Am Fam Physician; 1997 Nov; 56(7):1718, 1721. PubMed ID: 9371003
[No Abstract] [Full Text] [Related]
8. Strategy for surveillance of adverse drug events.
Bright RA
Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
[No Abstract] [Full Text] [Related]
9. When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg.
Woodcock J
FDA Consum; 1999; 33(5):8-11, 13. PubMed ID: 10522164
[No Abstract] [Full Text] [Related]
10. Recognizing and reporting adverse drug reactions.
Lucas LM; Colley CA
West J Med; 1992 Feb; 156(2):172-5. PubMed ID: 1536067
[TBL] [Abstract][Full Text] [Related]
11. The Food and Drug Administration's Drug Safety Oversight Board: an evolving paradigm for clinical input on drug safety topics.
Grandinetti CA; Osborne SF
Clin Pharmacol Ther; 2010 Aug; 88(2):269-74. PubMed ID: 20531466
[No Abstract] [Full Text] [Related]
12. Role of US poison centers in adverse drug reactions monitoring.
Chyka PA
Vet Hum Toxicol; 1999 Dec; 41(6):400-2. PubMed ID: 10592954
[TBL] [Abstract][Full Text] [Related]
13. MEDWatch: the new FDA medical products reporting program.
Kessler DA
Clin Pharm; 1993 Jul; 12(7):529-32. PubMed ID: 8354041
[No Abstract] [Full Text] [Related]
14. MEDWatch: the new FDA medical products reporting program.
Kessler DA
Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452
[No Abstract] [Full Text] [Related]
15. MEDWatch: medical products reporting program.
Minarik PA
Clin Nurse Spec; 1994 Mar; 8(2):74, 68. PubMed ID: 7882246
[No Abstract] [Full Text] [Related]
16. Drug safety special: chasing shadows.
Frantz S
Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592
[No Abstract] [Full Text] [Related]
17. Beware of new drugs, study suggests.
Levenson D
Rep Med Guidel Outcomes Res; 2002 May; 13(10):1-2, 5. PubMed ID: 12492085
[No Abstract] [Full Text] [Related]
18. Data incompatibility of adverse event reports electronically submitted to the AERS database.
Glass LM
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):212-3. PubMed ID: 18236510
[No Abstract] [Full Text] [Related]
19. MedWatch: the new medical products reporting program.
Couig MP
Crit Care Nurse; 1993 Aug; 13(4):13-7. PubMed ID: 8375176
[No Abstract] [Full Text] [Related]
20. A history of adverse drug experiences: Congress had ample evidence to support restrictions on the promotion of prescription drugs.
Waxman HA
Food Drug Law J; 2003; 58(3):299-312. PubMed ID: 14626231
[No Abstract] [Full Text] [Related]
[Next] [New Search]
